Summary | |
---|---|
Symbol | ICOSLG |
Name | inducible T-cell co-stimulator ligand |
Aliases | KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type I membrane protein |
Domain |
PF08205 CD80-like C2-set immunoglobulin domain PF07686 Immunoglobulin V-set domain |
Function |
Ligand for the T-cell-specific cell surface receptor ICOS. Acts as a costimulatory signal for T-cell proliferation and cytokine secretion; induces also B-cell proliferation and differentiation into plasma cells. Could play an important role in mediating local tissue responses to inflammatory conditions, as well as in modulating the secondary immune response by co-stimulating memory T-cell function (By similarity). |
Biological Process |
GO:0002250 adaptive immune response GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0006970 response to osmotic stress GO:0006972 hyperosmotic response GO:0007159 leukocyte cell-cell adhesion GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0031294 lymphocyte costimulation GO:0031295 T cell costimulation GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0042098 T cell proliferation GO:0042102 positive regulation of T cell proliferation GO:0042104 positive regulation of activated T cell proliferation GO:0042110 T cell activation GO:0042113 B cell activation GO:0042129 regulation of T cell proliferation GO:0045785 positive regulation of cell adhesion GO:0046006 regulation of activated T cell proliferation GO:0046651 lymphocyte proliferation GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050798 activated T cell proliferation GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0071593 lymphocyte aggregation GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion |
Molecular Function | - |
Cellular Component | - |
KEGG |
hsa04514 Cell adhesion molecules (CAMs) hsa04672 Intestinal immune network for IgA production |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-388841: Costimulation by the CD28 family R-HSA-168256: Immune System |
Summary | |
---|---|
Symbol | ICOSLG |
Name | inducible T-cell co-stimulator ligand |
Aliases | KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ICOSLG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between ICOSLG and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | ICOSLG |
Name | inducible T-cell co-stimulator ligand |
Aliases | KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ICOSLG in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ICOSLG |
Name | inducible T-cell co-stimulator ligand |
Aliases | KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ICOSLG in various data sets.
|
Points in the above scatter plot represent the mutation difference of ICOSLG in various data sets.
|
Summary | |
---|---|
Symbol | ICOSLG |
Name | inducible T-cell co-stimulator ligand |
Aliases | KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ICOSLG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ICOSLG |
Name | inducible T-cell co-stimulator ligand |
Aliases | KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ICOSLG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ICOSLG. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ICOSLG |
Name | inducible T-cell co-stimulator ligand |
Aliases | KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ICOSLG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ICOSLG |
Name | inducible T-cell co-stimulator ligand |
Aliases | KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ICOSLG expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ICOSLG |
Name | inducible T-cell co-stimulator ligand |
Aliases | KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ICOSLG and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | ICOSLG |
Name | inducible T-cell co-stimulator ligand |
Aliases | KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting ICOSLG collected from DrugBank database. |
There is no record. |